脂质体类型和给药途径在脂质体包裹的1-β-D-阿拉伯呋喃糖基胞嘧啶对小鼠L1210白血病抗肿瘤活性中的作用 - Suppr

Suppr

超能文献

Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.

作者信息

Rustum Y M, Dave C, Mayhew E, Papahadjopoulos D

出版信息

Cancer Res. 1979 Apr;39(4):1390-5.

PMID:421223

Abstract

摘要

相似文献

Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.

Cancer Res. 1979 Apr;39(4):1390-5.

Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.

Cancer Res. 1992 May 1;52(9):2431-9.

Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.

Cancer Res. 1989 Sep 15;49(18):5097-102.

Antitumor activity of a water-insoluble compound entrapped in liposomes on L1210 leukemia in mice.

J Natl Cancer Inst. 1983 Jun;70(6):1081-6.

Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes.

Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1923-8.

Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.

Cancer Res. 1980 Mar;40(3):630-3.

[Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].

Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 1):1437-45.

Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5'-adamantoate (NSC 117614) in L1210 leukemic mice.

Cancer Res. 1970 Apr;30(4):1047-54.

Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles.

Cancer Res. 1976 Dec;36(12):4406-11.

Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.

Cancer Res. 1970 Aug;30(8):2166-72.

引用本文的文献

Innovative approach to the detection of circulating tumor biomarkers: multi-dimensional application of liposome technology.

Lipids Health Dis. 2025 Apr 28;24(1):160. doi: 10.1186/s12944-025-02578-7.

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Ther Adv Hematol. 2014 Dec;5(6):211-20. doi: 10.1177/2040620714552615.

Clinical pharmacokinetics of cytarabine formulations.

Clin Pharmacokinet. 2002;41(10):705-18. doi: 10.2165/00003088-200241100-00002.

Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Drugs. 1993 Oct;46(4):618-38. doi: 10.2165/00003495-199346040-00004.

Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro.

Br J Cancer. 1982 Apr;45(4):559-64. doi: 10.1038/bjc.1982.92.

A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.

Proc Natl Acad Sci U S A. 1982 Jan;79(2):626-9. doi: 10.1073/pnas.79.2.626.

Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.

Proc Natl Acad Sci U S A. 1981 Mar;78(3):1873-7. doi: 10.1073/pnas.78.3.1873.

Liposomes as vehicles for cellular incorporation of biologically active macromolecules.

In Vitro. 1980 Jan;16(1):49-54. doi: 10.1007/BF02618199.

Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.

Cancer Chemother Pharmacol. 1988;21(4):299-307. doi: 10.1007/BF00264195.

Liposomes in chemo- and immunotherapy of cancer.

Lipids. 1987 Nov;22(11):891-6. doi: 10.1007/BF02535550.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验